Quantcast

Latest oral mucositis Stories

2011-07-19 07:30:00

DALLAS and NEW YORK, July 19, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, is being covered by TRICARE, the U.S. military health plan for active duty service members and retirees of the seven uniformed services, their family members, survivors and others...

2011-07-14 07:30:00

DALLAS and NEW YORK, July 14, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network. Reimbursement coverage for MuGard is now available with standard pharmacy benefit copayment. Placement in the pharmacy...

2011-05-17 07:00:00

DALLAS and NEW YORK, May 17, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that it had made significant progress with the commercial introduction of MuGard in the radiation oncology and medical oncology communities. MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating that has been shown to be...

a3d5fcb1aa5698e46744a8142a81e1241
2011-03-24 06:10:00

A NASA technology originally developed for plant growth experiments on space shuttle missions has successfully reduced the painful side effects resulting from chemotherapy and radiation treatment in bone marrow and stem cell transplant patients. In a two-year clinical trial, cancer patients undergoing bone marrow or stem cell transplants were given a far red/near infrared Light Emitting Diode treatment called High Emissivity Aluminiferous Luminescent Substrate, or HEALS, to treat oral...

2011-03-24 00:00:28

Treatment is being developed to reduce oral infection and pain associated with cancer treatments Honolulu, HI and Claremont CA (PRWEB) March 22, 2011 Biotech firm Synedgen announces the award of a competitive Phase II SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen's proprietary oral disease treatments. Under this 2-year $1.96 M effort, starting on April 1, Synedgen will accelerate the development of RegenasynTM, a topical treatment for oral...

2011-03-23 14:55:00

In the news release, NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002, issued 23-Mar-2011 by NephRx Corporation over PR Newswire, we are advised by the company that the original version should be disregarded. The complete, corrected release follows: NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease --Validates Potential Utility of NX002 as Treatment for this Common and Disabling Condition with Significant Unmet...

2011-03-23 06:30:00

KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis. Previously, NephRx reported that NX002 had demonstrated significant efficacy when tested in well-validated animal models of oral mucositis. Mucositis is a debilitating and often dose-limiting condition that affects more than 400,000 cancer patients who receive...

2010-10-15 07:00:00

DALLAS and NEW YORK, Oct. 15 /PRNewswire/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard - an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. In addition, the Company has received reimbursement for...

2010-10-11 07:00:00

DALLAS and NEW YORK, Oct. 11 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy. Some of the findings reported in the ESMO presentation included: MuGard provided a significant improvement and/or...

2010-10-07 06:30:00

KALAMAZOO, Mich., Oct. 7 /PRNewswire/ -- NephRx Corporation today announced that a new study has shown that its novel peptide NX002 demonstrated significant efficacy when tested in an animal model of oral mucositis. Mucositis is a debilitating and often dose-limiting side effect of many forms of cancer therapy that affects more than 400,000 patients who receive chemotherapy or radiation treatment in the U.S. each year. Current treatment options are very limited. "The efficacy...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related